Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?
Authors:
- Peter JüniPJPeter Jüni
- Anne Ws RutjesARAnne Ws Rutjes
- Paul A DieppePDPaul A Dieppe
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Reporting of 6-Month vs 12-Month Data in a Clinical Trial of CelecoxibJAMA, 2001
- Reporting of 6-Month vs 12-Month Data in a Clinical Trial of CelecoxibJAMA, 2001
- Exposure to Soy-Based Formula in InfancyJAMA, 2001
- Reporting of 6-Month vs 12-Month Data in a Clinical Trial of Celecoxib—ReplyJAMA, 2001
- Researchers deny any attempt to mislead the public over JAMA article on arthritis drugBMJ, 2001
- Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000
- Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysisProceedings of the National Academy of Sciences, 1999